Research topics
Drug discovery articles covering therapeutic targets, early drug development, pathway research, and emerging treatment ideas in IBD.
Page 1 of 2 · 90 articles
If you have Crohn’s disease with perianal fistulas and are treated with infliximab, this study suggests the drug is cleared faster and trough levels are often lower after standard dosing — which may mean you need higher...
The study points to creatine metabolism and CKB as regulators of intestinal epithelial health and shows hucMSC-derived vesicles can restore metabolic balance and reduce inflammation in preclinical models—highlighting a...
Patients on or considering infliximab may be interested because the paper identifies a possible molecular reason some people don’t respond and tests strategies that could, in principle, improve response to infliximab.
This preclinical study suggests clarithromycin may reduce colon inflammation in ulcerative colitis models and identifies Kv1.3 and the Th17/Treg balance as possible mechanisms — findings that could guide future...
This study uses transcriptomics, single‑cell data, and machine learning to nominate lactylation‑related genes as biomarkers and drug targets in ulcerative colitis, which could guide future biomarker or drug‑repurposing...
The study identifies acid ceramidase in myeloid cells as a regulator of sphingolipid metabolites and immune cell recruitment in a mouse model of chronic colitis, pointing to a possible new therapeutic target for IBD.
This preclinical work suggests the gut microbiota and tryptophan-derived metabolites that activate AhR may be important in reducing colitis-related inflammation — a potential route for future therapies relevant to...
Deep remission is an emerging treatment target in Crohn’s disease that combines symptoms and objective measures. A meaningful proportion of patients in VIVID-1 achieved corticosteroid-free deep remission with mirikizumab...
This study connects USP25 to NOD2–XIAP signaling and Crohn’s disease genetics, suggesting a possible target for future therapies or biomarkers relevant to IBD pathogenesis.
MMP-2 regulates tissue remodeling and inflammation in IBD; targeting it might help prevent barrier damage, chronic inflammation, or fibrosis but requires selective approaches to avoid harming normal repair processes.
Improving mesalazine delivery could increase drug reaching the colon and potentially improve treatment for ulcerative colitis. A formulation that both enhances dissolution/permeability and offers mechanistic synergy...
This study links a neutrophil protein (ANXA3) to both ulcerative colitis and ischaemic stroke and suggests a compound (ginsenoside Rb1) can bind ANXA3 and reduce neutrophil hyperactivation in lab tests — a potential...
This study identifies a new molecular pathway (JAK2–STAT4–AK4–mtDNA) linked to inflammatory macrophage activity in experimental colitis and presents a plant-derived alkaloid mixture (TAMR) that modulates that pathway....
The study links T cell metabolism and epigenetics to inflammation in IBD, highlighting GSK3β as a possible drug target. That could guide future therapies aimed at dampening pathogenic T cells in Crohn’s disease.
The study explores a novel, non-invasive way to deliver an IL-23–blocking protein to the gut using engineered Lactococcus lactis, which could eventually offer an alternative to systemic biologics for controlling...
People with IBD often hear about “treat-to-target” as a path to deeper healing.
This study explores a novel, non-invasive way to block IL-23 — an important inflammatory driver in IBD — by orally delivering small IL-23 inhibitors using engineered Lactococcus lactis in mouse colitis models.
This review explains how new drug classes and mechanism-focused strategies may change how IBD is treated, which could affect choices for patients who have not responded to existing therapies and inform discussions about...
The review identifies a novel molecular mechanism (S-palmitoylation) that may drive barrier dysfunction and intestinal inflammation in IBD, suggesting new non-immunosuppressive therapeutic targets that could eventually...
The review suggests NETs are elevated in IBD and that reducing NETs activity helped in animal models—so NETs could be a future therapeutic target and a biomarker of disease severity.
Organoid models aim to reproduce human intestinal biology more closely than traditional cell lines or animal models, which could improve understanding of IBD mechanisms and help develop or personalize therapies.
The study links macrophage CD38-driven NAD depletion to intestinal inflammation and shows that restoring NAD or blocking CD38 reduced disease in experimental colitis—suggesting a new metabolic target for IBD therapies.
The study links macrophage-driven CD38 activity to NAD+ depletion in colitis and shows that restoring NAD+ or blocking CD38 improved disease in experimental models — suggesting a new biological pathway that could lead to...
A company claims a novel quantum-based method has highlighted potential drug targets in diseases including Crohn’s disease, which could influence future drug discovery approaches. Investment by CDT Equity signals...
Regulatory approvals and trial activity for upadacitinib (Rinvoq) affect availability and prescribing patterns for immunomodulatory treatment options used across autoimmune and inflammatory diseases, including IBD.
The study connects many IBD genetic risk regions to specific genes and cell types, helping prioritize drug targets. It also nominates a known small molecule (entrectinib) as a repurposing candidate via NLRP3/NEK7...
The project investigates how TNFR1 and TNFR2 differently control epithelial repair in the colon—mechanisms that may explain why many patients on anti‑TNF biologics do not achieve lasting mucosal healing and could point...
The study suggests a new macrophage-linked mechanism (NINJ2 → ZBP1 → PANoptosis) that may drive intestinal inflammation in IBD and could become a target for future therapies or biomarkers.
S1PR1 drugs (S1P modulators) are an important drug class for IBD; a selective S1PR1 agonist with less S1PR3 activity could mean fewer heart-related side effects. This preclinical work highlights a possible new candidate...
Spatially resolved profiling could identify the specific cell neighborhoods and signaling circuits that drive disease in a person’s gut tissue, which may help predict who will respond to particular biologics or small...
This paper outlines research strategies aiming to deliver drugs more precisely to inflamed gut tissue and to reshape immune-cell behavior — advances that could eventually lead to safer, more targeted IBD treatments. It’s...
Macrophages are central regulators of intestinal inflammation and repair; understanding their diversity and how to modulate them could lead to new, more targeted treatments for Crohn's disease and ulcerative colitis.
This hire signals Coultreon is prioritizing commercial and development work on its SIK3 inhibitor COL-5671, which the company highlights as a potential oral treatment relevant to ulcerative colitis and Crohn’s disease.
If true, using infliximab drug-level modeling plus routine blood tests could help predict who has mucosal healing without immediate endoscopy, potentially reducing invasive procedures and improving monitoring for people...
The study proposes a new redox-regulatory pathway (Grx1–STAT6) that helps M2 macrophages drive tissue repair and colitis recovery in preclinical models, pointing to a possible new therapeutic target to promote...
Researchers found that nearly all people with UC have high-titer autoantibodies to the epithelial integrin αvβ6 that can precede disease and associate with worse outcomes. Understanding whether and how these antibodies...
This project explores a specific molecular pathway (WNT2B → NF-κB/IL‑6) that may protect the colon from inflammation. If validated, it could identify a new therapeutic target for IBD and help explain why some people...
Early-stage research suggests a specific probiotic strain may reduce inflammation and alter the gut microbiome and immune-related proteins in an animal model of ulcerative colitis, which could point to future therapeutic...
If you or someone you care for is not responding to anti‑TNF drugs for ulcerative colitis, this review explains biological reasons why that may happen and points toward research directions that could lead to better tests...
This paper identifies a herbal formula that improved inflammation and epithelial barrier repair in a mouse colitis model and highlights specific molecular pathways (CAV1/FAK/paxillin and metabolite pathways) that might...
PG is often linked with IBD and other systemic conditions, so approaches that treat the underlying comorbidity can improve ulcer healing and lower relapse risk. Patients with IBD who develop PG may benefit from therapies...
Patients and clinicians may notice fewer resources from a major drugmaker focused on a specific T‑cell antigen discovery effort for Crohn’s disease; researchers and investors should see this as a signal about how large...
The study identifies ABTB1 as a regulator that limits STAT3-driven Th17 differentiation and reduces severity in a mouse colitis model, suggesting a new molecular pathway relevant to IBD inflammation and a potential...
The study points to specific immune pathways (especially Th17 differentiation) and molecular targets that might explain DSP’s anti-inflammatory effects in ulcerative colitis, which could guide further preclinical and...
Understanding how different forms of programmed cell death in the gut lining contribute to barrier loss and inflammation could point to new therapeutic targets for IBD. The review also flags natural products and...
These results highlight a new cellular mechanism (macrophage-driven ECM changes) that may protect enteric neurons during intestinal inflammation — a process linked to symptoms and complications in IBD.
This article reports that Amgen is ending a Crohn’s disease target-discovery collaboration with TScan, which could slow or change an industry pathway for immune-targeted therapies discovered through that partnership....
This affects Crohn’s disease research funding and future drug-development pathways: a major pharmaceutical partner ended a collaboration that had aimed to discover T‑cell targets for Crohn’s disease, which could slow or...
